KNOXVILLE, TENN. (PRWEB) MAY 01, 2018
ChoiceSpine LP, a privately-held spinal device manufacturer based in Knoxville, TN, announced today at the American Association of Neurological Surgeons’ Annual Scientific Meeting the commercial launch of Tiger Shark, a 3D manufactured, titanium alloy interbody device created with a proprietary, organic, porous structure called BioBond.
With the aide of the BioBond porous structure, Tiger Shark was designed with a generous graft window, large boney ingrowth surface area, and a variety of anatomical footprints. The Tiger Shark interbody has a smooth, bulleted-shape, leading edge for fast insertion to accommodate posterior, transforaminal, and lateral surgical approaches.
“We are very excited to offer our customers a comprehensive solution, like Tiger Shark, that embodies our focus on cutting-edge technology,” said David Hannah, Director of Product Development at ChoiceSpine. “Along with our proprietary BioBond porous structure, Tiger Shark exhibits all of the necessary traits for powerful osseointegration, enhanced imaging properties, and solid biomechanical stability,” he continued.
Tiger Shark, which received a 510(k) clearance from the U.S. Food & Drug Administration (FDA) in January 2018, was designed to help surgeons restore sagittal balance with an interbody device that offers good post-operative radiographic assessment and favorable osseointegration possibilities. “The Tiger Shark design capitalizes on the additive manufacturing process, which yields an extra-large graft volume, and a hydrophilic nanosurface that will complement our biologics portfolio,” said Dr. Stephen Ainsworth, Executive Vice President of Strategy and Technology at ChoiceSpine.
ChoiceSpine is a privately held spinal implant company located in Knoxville, TN. Founded in 2006, Choice offers an extensive array of innovative, surgeon focused systems designed with the best clinical outcomes in mind. In addition, ChoiceSpine offers a full regenerative and osteobiologics portfolio including synthetics, DBM’s, structural allograft, and amnion allografts. With cutting edge technology in their Veo™ VLIF lateral fusion line to the incorporation of Hydroxyapetite (HA) in their PEEK® interbody systems, ChoiceSpine is committed to always staying ahead of market trends and to provide surgeons with dynamic solutions for their patients.